Literature DB >> 21875377

Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients.

Tatiana S Rodriguez-Reyna1, Andrea Hinojosa-Azaola, Cynthia Martinez-Reyes, Carlos A Nuñez-Alvarez, Rocío Torrico-Lavayen, José Luis García-Hernández, Javier Cabiedes-Contreras.   

Abstract

Systemic sclerosis (SSc) shows variable clinical expression among different ethnic groups. Herein, we describe the clinical features, prevalence of organ involvement, and autoantibody profile in Mexican Mestizo SSc patients and we compare them with patients from other ethnic groups.We included 139 SSc patients. They underwent clinical evaluation and were tested for antinuclear antibodies (ANA), anticentromere antibodies (ACA), anti-topoisomerase I, anti-RNA polymerase III, anti-U1 RNP, anti-U3 RNP, anti-U11/U12 RNP, anti-Th/To, anti-PM-Scl, anti-Ku, antinucleosome, anti-double-stranded DNA (dsDNA), anti-Sm, anti-SSA, and anti-SSB antibodies. Female predominance (93.5%) was noted; 56.8% of patients had limited cutaneous SSc; 91% had peripheral vascular involvement; 70% had joint involvement; 27% had musculoskeletal damage; 66% had gastrointestinal involvement; 41% had interstitial lung disease; 32% had pulmonary arterial hypertension (PAH); 11% had cardiac involvement; and in 1.4% renal involvement was observed. Our patients showed lower frequency of renal crisis and higher frequency of PAH than patients from other ethnic groups; also they showed higher frequency of ACA than Japanese and African American patients, higher frequency of anti-topoisomerase I than Caucasian and African American patients, higher frequency of anti-PM-Scl and anti-Ku and lower frequency of anti-RNA Pol III than the other ethnic groups. High frequencies of antinucleosome (41%) and anti-dsDNA (63%) were identified. SSc-specific autoantibody frequencies are different in our patients and in those from other ethnic groups; associations of autoantibodies with clinical manifestations are confirmed in our patients. Ethnicity and the interaction of gene and environmental factors may influence the clinical picture and autoantibody profile in SSc patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875377     DOI: 10.3109/08916934.2011.592886

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  14 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

Review 2.  The Ku complex: recent advances and emerging roles outside of non-homologous end-joining.

Authors:  Sanna Abbasi; Gursimran Parmar; Rachel D Kelly; Nileeka Balasuriya; Caroline Schild-Poulter
Journal:  Cell Mol Life Sci       Date:  2021-04-15       Impact factor: 9.261

Review 3.  The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

4.  New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays.

Authors:  Guang Song; Chaojun Hu; Heng Zhu; Li Wang; Fengchun Zhang; Yongzhe Li; Lin Wu
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

Review 5.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

6.  Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Authors:  Cristiane Mendes; Vilma S T Viana; Sandra G Pasoto; Elaine P Leon; Eloisa Bonfa; Percival D Sampaio-Barros
Journal:  Clin Rheumatol       Date:  2019-05-07       Impact factor: 2.980

7.  Systemic sclerosis manifestations and clinical outcomes in Hispanics/Latinos of the American Southwest.

Authors:  Sharon E Nunez; Angie Ariza-Hutchinson; Roderick A Fields; Jaime A Vondenberg; Rosemina A Patel; N Suzanne Emil; Maheswari Muruganandam; James I Gibb; Janet L Poole; Wilmer L Sibbitt
Journal:  J Scleroderma Relat Disord       Date:  2022-04-10

Review 8.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

Review 9.  Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement.

Authors:  Robyn T Domsic
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

10.  HLA Class I and II Blocks Are Associated to Susceptibility, Clinical Subtypes and Autoantibodies in Mexican Systemic Sclerosis (SSc) Patients.

Authors:  Tatiana S Rodriguez-Reyna; Pamela Mercado-Velázquez; Neng Yu; Sharon Alosco; Marina Ohashi; Tatiana Lebedeva; Alfredo Cruz-Lagunas; Carlos Núñez-Álvarez; Javier Cabiedes-Contreras; Gilberto Vargas-Alarcón; Julio Granados; Joaquin Zúñiga; Edmond Yunis
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.